Centessa Pharmaceuticals Plc Stock Price, News & Analysis

Centessa Pharmaceuticals (Nasdaq: CNTA) has appointed Karen Anderson as its new Chief People Officer, a role aimed at enhancing the company’s human resources and culture strategy. With over 25 years of experience in HR across biotechnology and pharmaceuticals, Anderson previously served as Chief Human Resources Officer at Mimecast and held senior positions at Alnylam Pharmaceuticals and Pfizer. CEO Saurabh Saha emphasized Anderson's strong track record in building high-performing teams, aligning with Centessa’s mission to develop transformational medicines for patients.

Centessa Pharmaceuticals (Nasdaq: CNTA) reported its third-quarter financial results, highlighting a cash position of $444.8 million as of September 30, 2022, ensuring operational funding into 2026. The company announced three significant milestones: the advancement of the pivotal program for SerpinPC in hemophilia B with the initiation of PRESent-5, an upcoming ASH presentation on December 10, 2022, for 18-month data on SerpinPC, and an IND submission for LB101 planned for late 2022. R&D expenses increased to $36.7 million from $25.9 million year-over-year.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced new efficacy and safety data from an 18-month treatment with SerpinPC in hemophilia patients, set for oral presentation at the 64th American Society of Hematology Annual Meeting in December 2022. The Phase 2a study shows a significant reduction in annualized bleeding rates, with data supporting SerpinPC's potential as a safe subcutaneous treatment option. The study highlights a dosing regimen of 60 mg every 4 weeks followed by 1.2 mg/kg bi-weekly, with positive tolerability results.

Centessa Pharmaceuticals (Nasdaq: CNTA) has announced its participation in two upcoming investor conferences. The first event is the Jefferies London Healthcare Conference on November 17, 2022, featuring a fireside chat at 10:55 AM GMT. The second is the Evercore ISI HealthCONx Conference, held virtually on November 30, 2022, at 3:30 PM ET.

Live webcasts and archived recordings will be accessible on the Centessa Pharmaceuticals investor relations website.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced that its oral orexin receptor 2 (OX2R) agonists showed potent efficacy in non-clinical models of narcolepsy type 1 (NT1). The findings will be presented at the Sleep Europe 2022 conference. The OX2R agonists demonstrated more than a thousand-fold selectivity for OX2R over OX1R and were effective in promoting wakefulness and reducing cataplexy in model mice. Centessa emphasizes its commitment to developing treatments for narcolepsy and acknowledges World Narcolepsy Day on September 22.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced that the FDA has granted Orphan Drug Designation for its drug candidate SerpinPC, aimed at treating hemophilia B. Registrational studies are set to commence in 4Q 2022. SerpinPC, designed to enhance thrombin generation, showed promising results in a Phase 2a study, demonstrating an 88% reduction in Annualized Bleeding Rate (ABR). The company also plans to release two-year follow-up data from the Phase 2a study in 4Q 2022, emphasizing the need for innovative treatment options.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced positive non-clinical pharmacokinetic and safety data for LB101, its first LockBody® candidate targeting solid tumors. The study showed systemic delivery of high doses of LB101 without hematological toxicity in non-human primates, indicating an improved therapeutic index and enhanced anti-tumor activity. The company plans to submit an Investigational New Drug (IND) application by late 2022, with management discussing the findings at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced participation in key investor conferences in September 2022. Notably, they will feature in the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, with a fireside chat at 8:45 AM ET in New York City. Following this, they will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 1:30 PM ET. Lastly, they will engage in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on September 28, 2022, at 11:30 AM ET. Live webcasts will be available on their website.

Centessa Pharmaceuticals (Nasdaq: CNTA) reported its Q2 2022 results, highlighting strong cash reserves of $484.2 million to fund operations into 2026. The firm plans to initiate registrational studies for SerpinPC in Hemophilia B by the end of 2022 and expects multiple clinical readouts across its pipeline over the next two years. However, it announced the discontinuation of ZF874 for Alpha-1 Antitrypsin Deficiency due to adverse events in early trials, concluding it would not achieve the desired profile.